Boston Scientific Corporation
BSXFull coverage—Boston Scientific Corporation
BSXNew York Stock ExchangeFull coverage
Q3 fiscal 2026 edition
A free account unlocks one dossier edition a month.
Create a free accountAlready have an account? Sign in
Summary
Free to read
Boston Scientific sells single-use medical devices, from heart catheters and implants to scopes and stents, mostly to hospitals. Its two growth engines have turned: electrophysiology sales fell 5.3% and Watchman 5.9% organically in the third quarter of 2026, as rival pulsed field ablation catheters took US share and doctors referred fewer patients for left atrial appendage closure. An eight-day cyber outage in August cut about 3 points from third-quarter growth, which came in at 1.5%, but both franchises were slowing before it, and management calls 2027 the trough. Moatsight estimates revenue of about $21.1 billion over the next four quarters, roughly flat, with a recovery resting on product launches now expected in 2028.
In the full dossier
- Part 1In brief
- Part 2Business explainer
- Part 3Earnings
- Part 4Valuation and projections
- Part 5What changed
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers